<DOC>
	<DOCNO>NCT00335569</DOCNO>
	<brief_summary>The purpose study evaluate clinical equivalence general tolerability two different subcutaneous hCG preparation ( hCG-IBSA , IBSA v Ovitrelle , Serono ) administer patient undergo IVF .</brief_summary>
	<brief_title>Clinical Tolerance Equivalence hCG-IBSA v Recombinant Human Chorionic Gonadotrophin Women Undergoing In Vitro Fertilisation</brief_title>
	<detailed_description>This prospective , multicenter , randomize , investigator blind , parallel group , active control , phase III clinical trial . Patients meet eligibility requirement study randomly assign receive either test drug ( hCG-IBSA , IBSA ) reference drug ( Ovitrelle , Serono ) . Investigators blind allow contact study medication ( supply box label manner reveal content box ) , request patient make statement investigator might indicate treatment assign . Equivalence test regard primary outcome variable establish whether two treatment indeed similarly effective .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<criteria>&gt; /=18 &lt; 40 year old ; BMI 18 30 kg/m2 ; le 3 previous complete cycle ; ovary present ; regular menstrual cycle 2535 day ; infertility attributable tubal factor , American Fertility Society grade I II endometriosis , male factor unexplained factor . within 12 month begin study , uterine cavity consistent expect normal function assess hysterosalpingogram , sonohystrogram hysteroscopic examination ; basal FSH level le 10 IU/L ; criterion hCG administration fulfil ( least 2 follicle diameter 16 mm , acceptable serum E2 concentration ) . male partner semen analysis within past 6 month show acceptable value seminal parameter , define &gt; 3x10 exp 6 spermatozoa/ml ; qualify receive 150 300 IU FSH start dose . age &lt; 18 &gt; = 40 year ; primary ovarian failure woman know poor responder ( i.e . require 300 IU FSH start dose previous treatment cycle less 3 oocyte retrieve , E2 serum concentration &lt; 3'000 pmol/L ) ; ovarian cyst &gt; 20 mm , enlargement due polycystic ovarian syndrome ; patient affect pathology associate contraindication pregnant ; hypersensitivity study medication ; bleed since stimulation ; uncontrolled thyroid adrenal dysfunction ; neoplasia ; severe impairment renal and/or hepatic function ; use concomitant medication might interfere study evaluation ( e.g . nonstudy hormonal medication , prostaglandin inhibitor , psychotropic agent ) ; 18 day FSH stimulation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Infertility , sterility , hCG , IVF</keyword>
</DOC>